Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Metabolic Changes in Hyperlipidemic Rats After The Administration of Xuezhikang

Author(s): Ke Su, Bingbao Chen, Xiaoting Tu, Luxin Ye, Xiaojie Lu, Zheng Yu, Xianqin Wang* and Xuezhi Yang*

Volume 17, Issue 6, 2021

Published on: 16 April, 2020

Page: [702 - 709] Pages: 8

DOI: 10.2174/1573412916999200416132311

Price: $65

Abstract

Background: Xuezhikang capsule, which contains cholesterol synthase inhibitors and a large number of natural statins, is put in the clinical application of lipid-lowering and so on. However, the specific use of dose, lipid-lowering effect and the relationship between metabolites are to be further studied.

Introduction: Metabonomics is the study of the relationship between the change of quantity and physiological changes from metabolites. At present, metabolomics has been widely used in drug development and testing. In this study, we developed a metabolomic method based on gas chromatographymass spectrometry (GC-MS) to find out hyperlipemia-related substances, and study the lipid-lowering mechanism of Xuezhikang.

Methods: Fifty SD rats (220 ± 20 g) were given a high-fat diet. After four-weeks modeling, they were randomly divided into semi-control groups, high fat group, simvastatin intervention group and Xuezhikang intervention group (0.23, 0.69, 1.15 mg/kg, low, medium, high), each dosage in eight rats. The control group (rest eight rats) were given a normal diet, and no specific treatment. The rats were sacrificed at the end of the experiment.

Results: The biochemical and body weight indexes of the normal control group and the high fat group were significantly different (P <0.05), which indicated that the model of hyperlipidemia was established success. There was a significant difference (P <0.05) between the Xuezhikang intervention group and high-fat control group (P <0.05), and hyperlipemia metabolomics related markers, oxalic acid, butyric acid, mannitol, glucose, glucuronic acid were found. Glucuronic acid and non-binding bilirubin combined with bilirubin, combined with some of the liver harmful substances, play a detoxification effect.

Conclusion: The results of metabonomics showed that the high-fat group and the control group have significant differences. Mannose, glucose content is relatively stable, lipid metabolism in high-fat group stearic acid, palmitic acid levels decreased, suggesting that high-fat diet disorders rat body lipid metabolism. It is worth mentioning that the experimental evaluation of rats, such as biochemical indicators and pathological results are prompted to model success, Xuezhikang intervention effect is more significant, consistent with the expected.

Keywords: Xuezhikang, hyperlipidemia, metabolomics, GC-MS, detoxification, glucuronic acid.

« Previous Next »
Graphical Abstract

[1]
Liu, Z.L.; Liu, J.P.; Zhang, A.L.; Wu, Q.; Ruan, Y.; Lewith, G.; Visconte, D. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst. Rev., 2011, (7), CD008305.
[PMID: 21735427]
[2]
Hyun, M.H.; Lee, Y.; Choi, B.G.; Na, J.O.; Choi, C.U.; Kim, J.W.; Kim, E.J.; Rha, S.W.; Park, C.G.; Lee, E.; Seo, H.S. Roles of achieved levels of low-density lipoprotein cholesterol and high-sensitivity C-reactive protein on cardiovascular outcome in statin therapy. Cardiovasc. Ther., 2019, 2019, 3824823.
[http://dx.doi.org/10.1155/2019/3824823] [PMID: 31885691]
[3]
Hawkes, N. High levels of bad cholesterol in early middle age are linked to CVD risk decades later, study finds. BMJ, 2019, 367, l6814.
[http://dx.doi.org/10.1136/bmj.l6814] [PMID: 31801728]
[4]
Florentin, M.; Kostapanos, M.S.; Kei, A.; Elisaf, M.S. Emerging drugs for hyperlipidaemia: an update. Expert Opin. Emerg. Drugs, 2014, 19(4), 471-488.
[http://dx.doi.org/10.1517/14728214.2014.976553] [PMID: 25356785]
[5]
Sicras-Mainar, A.; Sánchez-Álvarez, L.; Navarro-Artieda, R.; Darbà, J. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis. Lipids Health Dis., 2018, 17(1), 277.
[http://dx.doi.org/10.1186/s12944-018-0918-y] [PMID: 30522491]
[6]
Celik, M.; Celik, T. Alternate-day dosing of statins for secondary prevention of coronary artery disease/The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels. Anadolu Kardiyol. Derg., 2009, 9(3), 253.
[PMID: 19520663]
[7]
Ong, Y.C.; Aziz, Z. Systematic review of red yeast rice compared with simvastatin in dyslipidaemia. J. Clin. Pharm. Ther., 2016, 41(2), 170-179.
[http://dx.doi.org/10.1111/jcpt.12374] [PMID: 26956355]
[8]
Nie, C.; Zhang, F.; Ma, X.; Guo, R.; Zhou, S.; Zhao, L.; Xu, H.; Xiao, X.; Wang, Z. Determination of quality markers of Xuezhiling tablet for hyperlipidemia treatment. Phytomedicine, 2018, 44, 231-238.
[http://dx.doi.org/10.1016/j.phymed.2018.03.004] [PMID: 29631806]
[9]
Zhou, J.M.; Wang, H.M.; Lv, Y.Z.; Wang, Z.Z.; Xiao, W. Anti-atherosclerotic effect of Longxuetongluo Capsule in high cholesterol diet induced atherosclerosis model rats. Biomed. Pharmacother., 2018, 97, 793-801.
[http://dx.doi.org/10.1016/j.biopha.2017.08.141] [PMID: 29112932]
[10]
Huo, T.; Fang, Y.; Zhao, L.; Xiong, Z.; Zhang, Y.; Wang, Y.; Feng, C.; Yuan, M.; Wang, S.; Chen, M.; Jiang, H. 1HNMR-based metabonomic study of sub-chronic hepatotoxicity induced by realgar. J. Ethnopharmacol., 2016, 192, 1-9.
[http://dx.doi.org/10.1016/j.jep.2016.07.003] [PMID: 27377338]
[11]
Zhang, J.; Liang, R.; Wang, L.; Yan, R.; Hou, R.; Gao, S.; Yang, B. Effects of an aqueous extract of Crataegus pinnatifida Bge. var. major N.E.Br. fruit on experimental atherosclerosis in rats. J. Ethnopharmacol., 2013, 148(2), 563-569.
[http://dx.doi.org/10.1016/j.jep.2013.04.053] [PMID: 23685195]
[12]
Li, P.; Yang, Y.; Liu, M. Xuezhikang, extract of red yeast rice, inhibited tissue factor and hypercoagulable state through suppressing nicotinamide adenine dinucleotide phosphate oxidase and extracellular signal-regulated kinase activation. J. Cardiovasc. Pharmacol., 2011, 58(3), 307-318.
[http://dx.doi.org/10.1097/FJC.0b013e3182244a2d] [PMID: 21697731]
[13]
Li, X.M.; Shen, X.H.; Duan, Z.W.; Guo, S.R. A new monacolin analogue from Xuezhikang capsule. Yao Xue Xue Bao, 2011, 46(5), 564-567.
[PMID: 21800545]
[14]
Jänis, M.T.; Laaksonen, R.; Oresic, M. Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs. Expert Opin. Drug Metab. Toxicol., 2008, 4(6), 665-680.
[http://dx.doi.org/10.1517/17425255.4.6.665] [PMID: 18611110]
[15]
Zhang, A.; Sun, H.; Wang, P.; Han, Y.; Wang, X. Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity. Pharmazie, 2012, 67(2), 99-105.
[PMID: 22512077]
[16]
Bao, S.; Zhang, J.; Lin, Z.; Su, K.; Mo, J.; Hong, L.; Qian, S.; Chen, L.; Sun, F.; Wen, C.; Wu, Q.; Hu, L.; Lin, G.; Wang, X. Serum metabolic changes in rats after intragastric administration of dextromethorphan. Biomed. Chromatogr., 2017, 31(3), e3814.
[http://dx.doi.org/10.1002/bmc.3814] [PMID: 27528536]
[17]
Wen, C.; Zhang, M.; Zhang, Y.; Sun, F.; Ma, J.; Hu, L.; Lin, G.; Wang, X. Brain metabolomics in rats after administration of ketamine. Biomed. Chromatogr., 2016, 30(1), 81-84.
[http://dx.doi.org/10.1002/bmc.3518] [PMID: 26014584]
[18]
Wen, C.; Wang, Z.; Zhang, M.; Wang, S.; Geng, P.; Sun, F.; Chen, M.; Lin, G.; Hu, L.; Ma, J.; Wang, X. Metabolic changes in rat urine after acute paraquat poisoning and discriminated by support vector machine. Biomed. Chromatogr., 2016, 30(1), 75-80.
[http://dx.doi.org/10.1002/bmc.3627] [PMID: 26419410]
[19]
Lin, K.; Zhang, Q.; Liu, Z.; Yang, S.; Lin, Y.; Wen, C.; Zheng, Y. Effects of suberoylanilide hydroxamic acid on rat cytochrome P450 enzyme activities. Int. J. Clin. Exp. Pathol., 2015, 8(5), 5584-5590.
[PMID: 26191268]
[20]
Jia, Z.Y.; Bao, S.H.; Xu, Y.Y.; Liu, Z.Z.; Lin, Y.Y.; Yang, S.P.; Huang, X.L.; Wen, C.C.; Hu, L.F.; Yang, X.Z.; Wang, X.Q. Effect of dextromethorphan on CYP450 isoforms activity of rats. Int. J. Clin. Exp. Med., 2016, 9, 3600-3606.

Rights & Permissions Print Cite
Article Metrics
14
1
© 2024 Bentham Science Publishers | Privacy Policy